SCHEMBL24809172

SCHEMBL24809172

Cn1cnc2cc(Oc3ccc(N)c(F)c3Cl)ccc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.41
HPGD P15428 2/20 0.40
GAA P10253 2/20 0.40
DDB1 Q16531 1/20 0.37
CRBN Q96SW2 1/20 0.37
ALDH1A1 P00352 2/20 0.37
MAPT P10636 2/20 0.37
KDM4E B2RXH2 1/20 0.37
NPC1 O15118 3/20 0.36
RAB9A P51151 3/20 0.36
GFER P55789 1/20 0.36
MEN1 O00255 1/20 0.36
POLB P06746 1/20 0.36
ERBB2 P04626 6/20 0.36
FGFR1 P11362 1/20 0.36
GRM5 P41594 1/20 0.35
TP53 P04637 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
EGFR P00533 2/20 0.35
KDR P35968 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30051336 1.00 KMT2A (0.41) KMT2AHPGDGAADDB1CRBN
SCHEMBL24569478 0.87 KMT2A (0.44) KMT2AHPGDGAADDB1CRBN
SCHEMBL29887844 0.87 KMT2A (0.44) KMT2AHPGDGAADDB1CRBN
SCHEMBL24810325 0.83 GRM5 (0.41) GRM5
SCHEMBL30050278 0.81 KMT2A (0.40) KMT2AHPGDGAADDB1CRBN
SCHEMBL31475878 0.81 HCAR3 (0.36) KMT2AHPGDALDH1A1MAPTKDM4E
SCHEMBL24807834 0.81 KMT2A (0.41) KMT2AHPGDGAADDB1CRBN
SCHEMBL30050459 0.81 KMT2A (0.41) KMT2AHPGDGAADDB1CRBN
SCHEMBL23750168 0.80 KMT2A (0.46) KMT2AHPGDGAADDB1CRBN
SCHEMBL29935801 0.80 KMT2A (0.46) KMT2AHPGDGAADDB1CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230041385-A1 HER2 MUTATION INHIBITORS ARRAY BIOPHARMA INC. (US) 2023-02-09 US disclosed
WO-2022269531-A1 HER2 MUTATION INHIBITORS ARRAY BIOPHARMA INC. (US) 2022-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230041385-A1 HER2 MUTATION INHIBITORS ERBB2, EGFR, ERBB3 KMT2A 778/4885HPGD 2596/4885GAA 1431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.